Atlas FDA

PD-L1 IHC 22C3 pharmDx

FDA premarket approval P150013/S007 · decided 2017-11-20

Approval details

PMA number
P150013
Supplement
S007
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
PD-L1 IHC 22C3 pharmDx
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Applicant
Agilent Technologies, Inc.
Date received
2017-09-21
Decision date
2017-11-20
Days to decision
60 days
Decision code
APPR
Product code
PLS
Advisory committee
Pathology
Expedited review
No
Location
Santa Clara, CA
Statement
Approved for labeling changes to include results from additional non-clinical studies.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
GenetiSure Dx Postnatal Assay (K163367)Agilent Technologies, Inc.2017-08-11
MODIFICATION TO DEVICE LINK SYSTEM, MODEL M2376A (K012094)Agilent Technologies, Inc.2001-07-20
AGILENT M2636B TELEMON B MONITOR (TELEMON B) (K011824)Agilent Technologies, Inc.2001-07-02
HEARTSTREAM XL DEFIBIBRILLATOR/MONITOR, MODEL M4735A, HEARTSTREAM XLT DEFIBRILLATOR/MONITOR.MODEL M2500B (K010634)Agilent Technologies, Inc.2001-06-11
M2376A DEVICELINK SYSTEM, MODEL M2376A (K011578)Agilent Technologies, Inc.2001-06-08
HEARTSTREAM ATTENUATED DEFIBRILLATION PADS, MODEL M3870A (K003819)Agilent Technologies, Inc.2001-05-02
AGILENT INFORMATION CENTER SOFTWARE FOR M3150,M3151,M3153 AND M3154 (K011093)Agilent Technologies, Inc.2001-05-01
M2376A DEVICELINK SYSTEM (K010453)Agilent Technologies, Inc.2001-03-02